Homozygous A polymorphism of the complement C1qA(276) correlates with prolonged overall survival in patients with diffuse large B cell lymphoma treated with R-CHOP

BACKGROUND: The precise mechanism of action for rituximab (R) is not fully elucidated. Besides antibody-dependent cellular cytotoxicity (ADCC), complements may also play an important role in the clinical response to rituximab-based therapy in diffuse large B cell lymphoma (DLBCL). The purpose of thi...

Descripción completa

Detalles Bibliográficos
Autores principales: Jin, Xuan, Ding, Huirong, Ding, Ning, Fu, Zhiying, Song, Yuqin, Zhu, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Rapid Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3467177/
https://www.ncbi.nlm.nih.gov/pubmed/22897949
http://dx.doi.org/10.1186/1756-8722-5-51

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3467177/
https://www.ncbi.nlm.nih.gov/pubmed/22897949
http://dx.doi.org/10.1186/1756-8722-5-51

Ejemplares similares